RecruitingPhase 2NCT07022535

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Personalised Timing of Interval Debulking Surgery Based on KELIM After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer - a Pilot Study


Sponsor

The University of Hong Kong

Enrollment

18 participants

Start Date

May 28, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether tracking a blood marker called CA125 can help doctors choose the best time for surgery in women with advanced ovarian cancer who are first receiving chemotherapy to shrink their tumors. **You may be eligible if...** - You are 18 or older - You have been diagnosed with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer - Your cancer cannot be surgically removed right away, so you are starting chemotherapy first - You are in generally good health (able to carry out daily activities) - You have an elevated CA125 blood level at the start - You have had imaging scans (CT, PET-CT, or MRI) of your abdomen and pelvis - You are willing to have surgery and follow-up chemotherapy as part of the study **You may NOT be eligible if...** - Your cancer is a non-epithelial type (e.g., germ cell or sex cord tumor) - Your cancer can be fully removed with surgery right away - You are not healthy enough for surgery - You are pregnant - You started chemotherapy at another hospital more than one cycle ago Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTKELIM

(i) Patients with KELIM \>=1 will receive radiological assessment and undergo interval debulking surgery if the disease is operable. (ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery

DRUGCarboplatin plus Paclitaxel

Chemotherapy as neaodjuvant chemotherapy

PROCEDUREInterval debulking surgery

Interval debulking surgery


Locations(1)

The University of Hong Kong

Hong Kong, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07022535


Related Trials